Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Nuvation Bio ( (NUVB) ) is now available.
On January 11, 2026, Nuvation Bio entered into an exclusive license and collaboration agreement with Eisai granting Eisai rights to develop and commercialize taletrectinib (IBTROZI) across Europe, a wide swath of the Middle East and North Africa, Russia, Turkey, Canada, Australia, New Zealand and key Asia‑Pacific markets, in return for an upfront €50 million payment, a near-term €25 million regulatory milestone, up to €120 million in sales milestones, and tiered royalties on net sales. The deal, announced publicly on January 12, 2026, strengthens Nuvation Bio’s financial position and global reach for IBTROZI, complementing strong early U.S. commercial traction in 2025—432 new patient starts since the mid‑June FDA approval and preliminary net product revenue of $24.7 million for the year—while supporting continued investment in its pipeline, including a pivotal phase 3 trial of safusidenib and further development of its drug‑drug conjugate platform.
The most recent analyst rating on (NUVB) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Nuvation Bio stock, see the NUVB Stock Forecast page.
Spark’s Take on NUVB Stock
According to Spark, TipRanks’ AI Analyst, NUVB is a Neutral.
The score is driven by strong technical momentum and a favorable earnings-call backdrop tied to IBTROZI’s early launch traction and solid cash position. Offsetting these positives are weak financial fundamentals—very large ongoing losses and heavy cash burn—plus limited valuation support given the negative P/E and no dividend.
To see Spark’s full report on NUVB stock, click here.
More about Nuvation Bio
Nuvation Bio Inc. (NYSE: NUVB) is a global oncology company focused on developing targeted cancer therapies, including IBTROZI (taletrectinib), an oral next‑generation ROS1 inhibitor for ROS1‑positive non-small cell lung cancer, and safusidenib, which is being advanced for IDH1‑mutant gliomas. The company is transitioning into a commercial-stage biotech with a growing product portfolio and a strategic emphasis on expanding international market access and building a robust pipeline in difficult-to-treat cancers.
Average Trading Volume: 8,328,517
Technical Sentiment Signal: Buy
Current Market Cap: $2.91B
See more insights into NUVB stock on TipRanks’ Stock Analysis page.